Merck
CN
  • The valproate serum level in maintenance therapy for bipolar disorder in Japan.

The valproate serum level in maintenance therapy for bipolar disorder in Japan.

Hiroshima journal of medical sciences (2013-04-23)
Akihiko Machino, Hiroaki Jitsuiki, Yasumasa Okamoto, Satoru Izumitani, Yasuhiro Kimura, Katsuji Suzuki, Teruaki Tanaka, Takeshi Inoue, Tsukasa Koyama, Ken Wada, Yukari Masaoka, Takanobu Sasaki, Reiji Yoshimura, Jun Nakamura, Satsuki Sumitan, Tetsuro Ohmori, Shigeto Yamawaki
摘要

The appropriate therapeutic serum valproate level in maintenance therapy for bipolar disorder is not well known. We studied the serum valproate levels in seventeen bipolar I and twenty-four bipolar II disorder outpatients who had been treated with stable doses of valproate successfully for at least 12 months as prophylactic therapy. The trough serum valproate levels were 52.2 +/- 20.4 microg/ml in bipolar I, and 41.0 +/- 18.3 microg/ml in bipolar II disorder patients, respectively. A greater trend towards a higher trough level (p = 0.07) was indicated in the bipolar I disorder group. We speculate that these valproate levels may be an approximation to the appropriate valproate levels in maintenance therapy and that there may be a correlation between the level of valproate required for stabilization and the subtype of the bipolar disorder. However, when interpreting these findings, certain limitations to this study? Need to be taken into account as follows. The sample size was small. We could not look at a group on valproate that had relapsed and a group that had dropped out of maintenance therapy. Further studies are needed.

材料
货号
品牌
产品描述

Supelco
丙戊酸, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
2-丙基戊酸
Supelco
丙戊酸标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®